Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2010

View Archived Issues

Sanofi-aventis discovers new casein kinase I inhibitors

Lorcaserin reduces body weight in phase III BLOOM/BLOSSOM trials

Belatacept superior to ciclosporin in renal transplant recipients

AstraZeneca synthesizes new ATR kinase inhibitors as oncolytics

Nhwa Pharma describes new serotonin 5-HT2A antagonists

Sigma-Tau retinoid derivatives may be active against metastatic cancer

Betagenon claims new AMPK activators

ONO-5334 has beneficial effects on bone in postmenopausal women

Elevated GGT in serum is a risk factor for breast cancer

Linifanib/mFOLFOX6 combination shows promise in metastatic colorectal cancer

LCT reports additional phase II data on DiabeCell in type 1 diabetes

HGS and Lonza form commercial manufacturing agreement for Benlysta

Hologic resubmits Gestiva NDA for prevention of preterm birth

Presidio Pharma completes phase Ia trial of HCV inhibitor PPI-461

Silence Therapeutics and AstraZeneca extend siRNA development collaboration

Aestus and Eisai to develop new therapeutics for psychiatric disorders

Innocoll submits SPA for phase III trial of Cogenzia for foot ulcer infections in diabetes

Trevena secures financing for TRV-120027 in acute heart failure

Peregrine begins second phase IIb trial of bavituximab in NSCLC

ChemGenex to submit new NDA for Omapro as third-line CML therapy

Cubist's phase II safety trial of Cubicin in prosthetic joint infections meets objectives

ISTA begins phase I/II trial of bepotastine besilate nasal spray for seasonal allergic rhinitis

BTG issues annual general meeting and interim management statement

Nabi completes enrollment in first of two phase III NicVAX trials

FDA clears Starpharma's phase II trial of VivaGel in bacterial vaginosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...